Bellevue Asset Management’s Sutro Biopharma STRO Stock Holding History

Bellevue Asset Management’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-8	Closed	-$1K	–	571
2021 Q4	$1K	Sell	8 -1	-11%	-$179	﹤0.01%	556
2021 Q3	$2K	Hold	9	–	–	﹤0.01%	540
2021 Q2	$2K	Sell	9 -1	-10%	-$196	﹤0.01%	542
2021 Q1	$2K	Buy	10 +4	+67%	+$949	﹤0.01%	599
2020 Q4	$2K	Buy	+6	New	+$993	﹤0.01%	606

Other funds holding STRO

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Bellevue Asset Management's STRO Position: Q1 2022 in Review

Bellevue Asset Management sold out of Sutro Biopharma (STRO) in Q1 2022, closing a stake of 8 shares — an estimated $1K sold.

Bellevue Asset Management first reported a position in STRO in Q4 2020 and held it in 5 quarters. The position peaked at $2K in Q3 2021. 114 funds tracked by Wall St. Rank hold STRO as of Q1 2022.

Bellevue Asset Management reported no remaining Sutro Biopharma position as of Q1 2022 after selling out during the quarter.
Bellevue Asset Management sold 8 Sutro Biopharma shares in Q1 2022, an estimated $1K.
Bellevue Asset Management first reported a position in Sutro Biopharma in Q4 2020 and held it in 5 quarters.
Bellevue Asset Management's Sutro Biopharma position peaked at $2K in Q3 2021.
114 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2022.

Based on Bellevue Asset Management's 13F filing for Q1 2022, filed 11 May 2022.